Circulating tumor cells predict survival in patients with metastatic prostate cancer
- 1 April 2005
- Vol. 65 (4), 713-718
- https://doi.org/10.1016/j.urology.2004.11.006
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- THE NATURAL HISTORY OF ANDROGEN INDEPENDENT PROSTATE CANCERJournal of Urology, 2004
- Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancerUrology, 2004
- Epidemiology of prostate cancerUrology, 2003
- Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancerUrology, 2003
- Determinants of Prostate Cancer Specific Survival Following Radiation Therapy During the Prostate Specific Antigen EraJournal of Urology, 2003
- Surrogate End Point for Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation TherapyJNCI Journal of the National Cancer Institute, 2003
- Variables in predicting survival based on treating “PSA-Only” relapseUrologic Oncology: Seminars and Original Investigations, 2003
- Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate CancerJournal of Clinical Oncology, 2003
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working GroupJournal of Clinical Oncology, 1999
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999